Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Details $250M Synthetic Share Repurchase Plan

NEW YORK (GenomeWeb) – Qiagen on Wednesday disclosed details for the completion of an approximately $250 million synthetic share repurchase plan that combines a direct capital repayment with a reverse stock split.

Qiagen announced the share repurchase in August. It involves an approach used by various large, multinational Dutch companies to provide returns to all shareholders faster and more efficiently than a traditional open-market share repurchase, Qiagen noted.

Under the terms of the repurchase, every 27 issue Qiagen shares will be consolidated into 26 Qiagen shares. Following the implementation of the consolidation, Qiagen will issue to its shareholders a capital repayment of $1.04 per pre-split share held by each shareholder.

The last day of trading of the pre-split shares on Nasdaq and the Frankfurt Stock Exchange will be Jan. 24. Beginning on Jan. 25, the consolidated Qiagen shares, excluding the entitlement to the capital repayment, will start to trade on Nasdaq and the Frankfurt Stock Exchange under the company's current ticker symbols QGEN and QIA, respectively.

Qiagen noted that the synthetic share repurchase is part of a commitment announced by the company in July 2016 to return $300 million to shareholders by the end of 2017.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.